Top

Published in:

01-05-2020 | Glioblastoma | Clinical Study

Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database

Authors: Victor M. Lu, Ashish H. Shah, Daniel G. Eichberg, Alfredo Quinones-Hinojosa, Yoshua Esquenazi, Ricardo J. Komotar, Michael E. Ivan

Published in: Journal of Neuro-Oncology | Issue 3/2020

Abstract

Background

Access to treatment for glioblastoma (GBM) can be impacted by multiple demographic parameters. Barriers specific to the Hispanic population of the United States (US) are not fully understood. Therefore, the aim of this study was to elucidate geographic disparities for access to GBM treatment in the US Hispanic population.

Methods

All GBM patients with known Hispanic ethnicity status (and Caucasian race) in the US National Cancer Database (NCDB) between the years 2005–2016 were retrospectively reviewed. Treatment statuses of surgical resection, chemotherapy, radiation therapy and triple therapy (resection, chemotherapy and radiation) were summarized, and analyzed by comparison and regression analyses over US Census regions.

Results

A total cohort size of 40,232 Caucasian GBM patients were included, with 3,111 (8%) identifying as Hispanic. The odds of treatment by chemotherapy (OR 0.78, P < 0.01), radiation therapy (OR 0.82, P < 0.01) and triple therapy (OR 0.84, P < 0.01) were all significantly lower in the Hispanic group versus non-Hispanic group. The odds of being treated in the Hispanic group were significantly lower in multiple Census regions with respect to surgical resection (New England, OR 0.51; Mountain, OR 0.68), chemotherapy (East North Central, OR 0.77; Middle Atlantic, OR 0.71; Pacific, OR 0.77), radiation therapy (Middle Atlantic, OR 0.77) and triple therapy (New England, OR 0.49; Middle Atlantic, OR 0.87; Pacific, OR 0.84). Significant barriers to triple therapy in the Hispanic group within these regions were older age (OR 0.97; P < 0.01), treatment in a community facility (OR 0.85, P = 0.03), lack of insurance (OR 0.71, P = 0.03), yearly income < $40,227 (OR 0.69, P < 0.01), low education levels (OR 0.75, P = 0.03) and presence of co-morbidity (OR 0.82; P < 0.01).

Conclusions

Currently in the US, there exists heterogenous geographic disparities for Hispanic GBM patients to access different treatments compared to non-Hispanic patients. Multiple circumstances can influence access to treatment within the Hispanic community of these regions, and greater investigation with more granularity required to reveal mechanisms in which these disparities may be addressed in the future.

Available only for authorised users

Mojica CM, Flores B, Ketchum NS, Liang Y (2017) Health care access, utilization, and cancer screening among low-income Latina Women. Hisp Health Care Int 15(4):160–165. https://doi.org/10.1177/1540415317735343 CrossRefPubMed

Alvarez E, Keegan T, Johnston EE, Haile R, Sanders L, Saynina O, Chamberlain LJ (2017) Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers. Cancer 123(13):2516–2523. https://doi.org/10.1002/cncr.30562 CrossRefPubMed

Yanez B, McGinty HL, Buitrago D, Ramirez AG, Penedo FJ (2016) Cancer outcomes in Hispanics/Latinos in the United States: an integrative review and conceptual model of determinants of health. J Lat Psychol 4(2):114–129. https://doi.org/10.1037/lat0000055 CrossRefPubMedPubMedCentral

Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D (2015) Jemal A (2015) Cancer statistics for Hispanics/Latinos. CA Cancer J Clin 65(6):457–480. https://doi.org/10.3322/caac.21314 CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

Weller M (2018) Next generation neuro-oncology. Eur J Cancer 96:1–5. https://doi.org/10.1016/j.ejca.2018.03.016 CrossRefPubMed

Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N (2018) Current challenges and opportunities in treating glioblastoma. Pharmacol Rev 70(3):412–445. https://doi.org/10.1124/pr.117.014944 CrossRefPubMedPubMedCentral

Chandra A, Rick JW, Dalle Ore C, Lau D, Nguyen AT, Carrera D, Bonte A, Molinaro AM, Theodosopoulos PV, McDermott MW, Berger MS, Aghi MK (2018) Disparities in health care determine prognosis in newly diagnosed glioblastoma. Neurosurg Focus 44(6):E16. https://doi.org/10.3171/2018.3.Focus1852 CrossRefPubMedPubMedCentral

Mukherjee D, Zaidi HA, Kosztowski T, Chaichana KL, Brem H, Chang DC, Quinones-Hinojosa A (2010) Disparities in access to neuro-oncologic care in the United States. Arch Surg 145(3):247–253. https://doi.org/10.1001/archsurg.2009.288 CrossRefPubMed

10.

Mukherjee D, Kosztowski T, Zaidi HA, Jallo G, Carson BS, Chang DC, Quinones-Hinojosa A (2009) Disparities in access to pediatric neurooncological surgery in the United States. Pediatrics 124(4):e688–696. https://doi.org/10.1542/peds.2009-0377 CrossRefPubMed

11.

Mukherjee D, Zaidi HA, Kosztowski T, Chaichana KL, Salvatori R, Chang DC, Quinones-Hinojosa A (2009) Predictors of access to pituitary tumor resection in the United States, 1988–2005. Eur J Endocrinol 161(2):259–265. https://doi.org/10.1530/eje-09-0043 CrossRefPubMed

12.

Lerro CC, Robbins AS, Phillips JL, Stewart AK (2013) Comparison of cases captured in the national cancer data base with those in population-based central cancer registries. Ann Surg Oncol 20(6):1759–1765. https://doi.org/10.1245/s10434-013-2901-1 CrossRefPubMed

13.

Dressler EV, Liu M, Garcia CR, Dolecek TA, Pittman T, Huang B, Villano JL (2019) Patterns and disparities of care in glioblastoma. Neurooncol Pract 6(1):37–46. https://doi.org/10.1093/nop/npy014 CrossRefPubMed

14.

Rhome R, Fisher R, Hormigo A, Parikh RR (2016) Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. J Neurooncol 128(2):241–250. https://doi.org/10.1007/s11060-016-2101-5 CrossRefPubMed

15.

Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E (2018) Delays in diagnosis and treatment of breast cancer: a safety-net population profile. J Natl Compr Canc Netw 16(12):1451–1457. https://doi.org/10.6004/jnccn.2018.7067 CrossRefPubMed

16.

Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K, Royal R, Mansfield P, Badgwell BD (2018) Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: analysis of the national cancer data base, 2006–2014. Cancer 124(5):998–1007. https://doi.org/10.1002/cncr.31155 CrossRefPubMed

17.

Liederbach E, Lewis CM, Yao K, Brockstein BE, Wang C-H, Lutfi W, Bhayani MK (2015) A contemporary analysis of surgical trends in the treatment of squamous cell carcinoma of the oropharynx from 1998 to 2012: a report from the national cancer database. Ann Surg Oncol 22(13):4422–4431. https://doi.org/10.1245/s10434-015-4560-x CrossRefPubMed

18.

Caram MEV, Ross R, Lin P, Mukherjee B (2019) Factors associated with use of sipuleucel-t to treat patients with advanced prostate cancer. JAMA Netw Open 2(4):e192589–e192589. https://doi.org/10.1001/jamanetworkopen.2019.2589 CrossRefPubMedPubMedCentral

19.

Pan IW, Ferguson SD, Lam S (2015) Patient and treatment factors associated with survival among adult glioblastoma patients: a USA population-based study from 2000–010. J Clin Neurosci 22(10):1575–1581. https://doi.org/10.1016/j.jocn.2015.03.032 CrossRefPubMed

20.

Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS (2018) Adult glioma incidence and survival by race or ethnicity in the united states from 2000 to 2014. JAMA Oncol 4(9):1254–1262. https://doi.org/10.1001/jamaoncol.2018.1789 CrossRefPubMedPubMedCentral

21.

Wu C-C, Wang TJC, Jani A, Estrada JP, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb CS, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, McKhann GM 2nd (2016) A modern radiotherapy series of survival in hispanic patients with glioblastoma. World Neurosurg 88:260–269. https://doi.org/10.1016/j.wneu.2015.12.081 CrossRefPubMed

22.

Tang J, Shao W, Dorak MT, Li Y, Miike R, Lobashevsky E, Wiencke JK, Wrensch M, Kaslow RA, Cobbs CS (2005) Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev 14(8):2040–2044. https://doi.org/10.1158/1055-9965.EPI-05-0136 CrossRefPubMed

23.

Shabihkhani M, Telesca D, Movassaghi M, Naeini YB, Naeini KM, Hojat SA, Gupta D, Lucey GM, Ontiveros M, Wang MW, Hanna LS, Sanchez DE, Mareninov S, Khanlou N, Vinters HV, Bergsneider M, Nghiemphu PL, Lai A, Liau LM, Cloughesy TF, Yong WH (2017) Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. J Neurooncol 132(2):351–358. https://doi.org/10.1007/s11060-017-2377-0 CrossRefPubMed

24.

Brown DA, Himes BT, Kerezoudis P, Chilinda-Salter YM, Grewal SS, Spear JA, Bydon M, Burns TC, Parney IF (2018) Insurance correlates with improved access to care and outcome among glioblastoma patients. Neuro Oncol 20(10):1374–1382. https://doi.org/10.1093/neuonc/noy102 CrossRefPubMedPubMedCentral

25.

Edward J, Morris S, Mataoui F, Granberry P, Williams MV, Torres I (2018) The impact of health and health insurance literacy on access to care for Hispanic/Latino communities. Public Health Nurs 35(3):176–183. https://doi.org/10.1111/phn.12385 CrossRefPubMed

26.

Ghaddar S, Byun J, Krishnaswami J (2018) Health insurance literacy and awareness of the affordable care act in a vulnerable Hispanic population. Patient Educ Couns 101(12):2233–2240. https://doi.org/10.1016/j.pec.2018.08.033 CrossRefPubMed

27.

van der Goes DN, Santos R (2018) Determinants of private health insurance coverage among Mexican American men 2010–2013. J Med Econ 21(11):1139–1143. https://doi.org/10.1080/13696998.2018.1515083 CrossRefPubMed

28.

O'Connor JM, Sedghi T, Dhodapkar M, Kane MJ, Gross CP (2018) Factors associated with cancer disparities among low-, medium-, and high-income US Counties. JAMA Netw Open 1(6):e183146. https://doi.org/10.1001/jamanetworkopen.2018.3146 CrossRefPubMedPubMedCentral

29.

Akee R, Jones MR, Porter SR (2019) Race matters: income shares, income inequality, and income mobility for all US races. Demography 56(3):999–1021. https://doi.org/10.1007/s13524-019-00773-7 CrossRefPubMed

30.

Villanueva C, Chang J, Bartell SM, Ziogas A, Bristow R, Vieira VM (2019) Contribution of geographic location to disparities in ovarian cancer treatment. J Natl Compr Canc Netw 17(11):1318–1329. https://doi.org/10.6004/jnccn.2019.7325 CrossRefPubMedPubMedCentral

31.

Kamara D, Weil J, Youngblom J, Guerra C, Joseph G (2018) Cancer counseling of low-income limited english proficient latina women using medical interpreters: implications for shared decision-making. J Genet Couns 27(1):155–168. https://doi.org/10.1007/s10897-017-0132-5 CrossRefPubMed

32.

Ilowite MF, Cronin AM, Kang TI, Mack JW (2017) Disparities in prognosis communication among parents of children with cancer: the impact of race and ethnicity. Cancer 123(20):3995–4003. https://doi.org/10.1002/cncr.30960 CrossRefPubMed

33.

Cadet TJ, Burke SL, Stewart K, Howard T, Schonberg M (2017) Cultural and emotional determinants of cervical cancer screening among older Hispanic women. Health Care Women Int 38(12):1289–1312. https://doi.org/10.1080/07399332.2017.1364740 CrossRefPubMedPubMedCentral

34.

Bakk L, Cadet TJ (2018) Awareness of the medicare part D low-income subsidy among older non-Hispanic blacks and Hispanics. Soc Work Public Health 33(4):250–258. https://doi.org/10.1080/19371918.2018.1462285 CrossRefPubMed

35.

Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, Martinez-Tyson D, Jemal A (2018) Siegel RL (2018) Cancer statistics for Hispanics/Latinos. CA Cancer J Clin 68(6):425–445. https://doi.org/10.3322/caac.21494 CrossRefPubMed

36.

Manuel JI (2018) Racial/ethnic and gender disparities in health care use and access. Health Serv Res 53(3):1407–1429. https://doi.org/10.1111/1475-6773.12705 CrossRefPubMed

37.

Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patiño A, Arrieta O, Hakim EJ, Hakim F, Mejía JA, Useche N, Bermúdez S, Carranza H, Vargas C, Otero J, Mayor LC, Ortíz LD, Franco S, Ortíz C, Gil-Gil M, Balaña C, Zatarain-Barrón ZL (2018) Efficacy and safety of Levetiracetam vs other antiepileptic drugs in Hispanic patients with glioblastoma. J Neurooncol 136(2):363–371. https://doi.org/10.1007/s11060-017-2660-0 CrossRefPubMed

38.

Dickmann LJ, Schutzman JL (2018) Racial and ethnic composition of cancer clinical drug trials: how diverse are we? Oncologist 23(2):243–246. https://doi.org/10.1634/theoncologist.2017-0237 CrossRefPubMed

39.

Duong C, Nguyen T, Sheppard JP, Ong V, Chung LK, Nagasawa DT, Yang I (2017) Genomic and molecular characterization of brain tumors in asian and non-asian patients of Los Angeles: a single institution analysis. Brain Tumor Res Treat 5(2):64–69. https://doi.org/10.14791/btrt.2017.5.2.64 CrossRefPubMedPubMedCentral

40.

Martinez Tyson D, Medina-Ramirez P, Flores AM, Siegel R, Aguado Loi C (2018) Unpacking hispanic ethnicity-cancer mortality differentials among hispanic subgroups in the United States, 2004–2014. Front Public Health 6:219. https://doi.org/10.3389/fpubh.2018.00219 CrossRefPubMedPubMedCentral

Title: Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database
Authors: Victor M. Lu
Ashish H. Shah
Daniel G. Eichberg
Alfredo Quinones-Hinojosa
Yoshua Esquenazi
Ricardo J. Komotar
Michael E. Ivan
Publication date: 01-05-2020
Publisher: Springer US
Keywords: Glioblastoma
Glioblastoma
Glioblastoma
Cytostatic Therapy
Published in: Journal of Neuro-Oncology / Issue 3/2020
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03480-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

End-of-life care for glioma patients; the caregivers’ perspective

Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio is a predictor of the prognosis for brain metastases

Incidence of high grade gliomas presenting as radiographically non-enhancing lesions: experience in 111 surgically treated non-enhancing gliomas with tissue diagnosis

Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma

Carbon ion radiotherapy for skull base chordomas and chondrosarcomas: a systematic review and meta-analysis of local control, survival, and toxicity outcomes

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1